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Introduction 49 50 Clinical diagnosis is the current standard for identifying invasive Neisseria meningitidis 51 infection (meningococcal disease, MD) despite the signs and symptoms being notoriously 52 non-specific, especially in young children. 1, 2 Although MD can progress very quickly, the 53 typical signs and symptoms (if present) do not appear until a median of 13 to 22 hours after 54 the first onset of symptoms, and half of children who present to their GP in the early stages 55 of MD are not referred or admitted to hospital at the first presentation. 3 Conversely, fear of 56 missing the diagnosis also leads to overtreatment. 4 Most children admitted and treated as 57 suspected MD turn out to have a less serious infection, and a previous study in our hospital 58 found two thirds of children treated as possible MD had an alternative diagnosis. 5 Although 59 introduction of an effective vaccine against serogroup B meningococcus should reduce the 60 prevalence of meningococcal infection, 6 there is considerable scope to improve diagnostic 61 testing. 62
63
Laboratory tests serve only to confirm the clinical diagnosis, as definitive results are rarely 64 available in time to influence clinical decision making. 7 We previously developed a rapid 65 and effective molecular test based on 'loop-mediated isothermal amplification' (LAMP) to 66 detect meningococcal DNA (ctrA gene) in clinical specimens. 8 This assay gives equivalent 67 performance to the current UK reference molecular test (TaqMan ® real-time PCR 9-12 ) but is 68 faster and less expensive. In the UK, the National Institute of Health and Care Excellence 69 (NICE) recognises that molecular (PCR) testing of sterile site specimens for meningococcus 70 is very effective, but also notes that PCR is not available in most hospitals due to resource 71 limitations. 13 72 73 Detection of meningococcal DNA in a sterile site (blood or CSF) specimen confirms a 74 diagnosis of invasive MD, 13 but this testing assumes that a level of clinical suspicion is 75 already present. Collecting blood or CSF specimens from every patient with pyrexia but 76 without the classical features of meningococcal infection is neither feasible nor desirable. 77
Nevertheless, this group will include the small number of patients who have early-stage MD 78 and who are at risk of being falsely reassured. Obtaining a nasopharyngeal specimen is 79 relatively non-invasive, although current advice in the UK is not to test these for 80 meningococcus due to the risk of detecting asymptomatic carriage. 13 We have previously 81 shown, using sensitive and specific PCR methods, that carriage rates of pathogenic 82 (capsular) meningococci in young children are very low. 14 Our previous study found 83 molecular testing of throat swabs had a sensitivity of 81% and a specificity of 100% for 84 diagnosis of MD. If a suitable molecular assay to detect capsular meningococci is used, we 85
propose that near-patient testing of non-invasive respiratory specimens can provide valuable 86 information to clinicians. 87
88
We report here a study to evaluate the diagnostic accuracy of meningococcal LAMP as a 89 near-patient test on respiratory (combined nasal and throat swab) and blood specimens in 90 patients with suspected MD. Respiratory, blood and CSF specimens were tested in the 91 laboratory using a reference PCR assay. Conventional blood and CSF culture methods were 92 used, as per normal clinical practice, and the diagnostic performance of standard 'non 93 specific' laboratory tests was evaluated for comparison.
Study design, inclusion criteria and specimens 97 98
The study was approved by the Office for Research Ethics Committee Northern Ireland 99
[reference 09/NIR02/43]. Clinical specimens were collected as per normal Royal Belfast 100
Hospital for Sick Children (RBHSC) practice, with near-patient testing of aliquots as 101 described below. Written informed consent was obtained from the parents of all study 102 participants before their near-patient test results were included in the study. 103
104
The study was designed as a prospective cohort study of diagnostic accuracy. Children (aged 105 0 to 13 years) presenting to the emergency department between November 2009 and January 106 2012 were eligible for inclusion. Patients with suspected meningitis or septicaemia entered 107 a clinical care pathway and had a standard 'meningococcal pack' of investigations ( Table  108 1). This group included those whom the admitting doctor suspected might have MD: 109 children with fever, unwell appearance, non-blanching rash, signs of meningitis or signs of 110 septicaemia. 111 6 reagents that were prepared in advance and stored frozen in the emergency department. 120
Unlike molecular amplification methods such as PCR, positive LAMP reactions can be 121 identified by visual inspection of the reaction tubes after incubation at an appropriate 122 temperature. In this study, four near-patient LAMP tests were run for each patient (EDTA 123 blood; combined nasopharyngeal swab; positive control; negative control) and test results 124 were read after incubation at 63°C for 60 minutes. In total, 161 patients had a 'meningococcal pack' of investigations and were tested. 151
Subsequently, one declined consent, and a further 12 were not approached for consent (two 152 died; one child protection case; two discharged early; seven transferred to other units). The 153 remaining 148 patients were consented into the study. Most were under five years old 154 (median 11 months; range 17 days -12.5 years) and 57% were male gender. 27/148 (18%) 155 were found to have laboratory confirmed MD, and 121/148 (82%) had other conditions 156 (Table 2 ). Only 7/27 (26%) of the children with confirmed MD had meningococcus isolated 157 in blood culture, and only one of these was positive by blood culture alone. 26/27 (96%) 158
were positive for meningococcal DNA in their blood by PCR. 8/27 (30%) of the children 159 with confirmed MD had a lumbar puncture to obtain CSF (Table 3 ) and all were culture 160 negative. Seven had CSF analysed for meningococcal DNA in the laboratory and 6/7 (86%) 161 were positive. Antibiotics had been given prior to lumbar puncture to all patients in our 162 study, giving CSF culture a sensitivity of zero. In contrast, molecular testing of CSF was 163 clearly useful, although none of the patients here were positive by molecular testing of CSF 164 alone. 165 166 11 children with laboratory confirmed MD had viral co-infections diagnosed by routine 167 molecular virology testing, and three were infected with more than one virus. One child was 168 positive in blood for enterovirus, seven were positive for respiratory viruses (picornavirus, 169 rhinovirus, enterovirus, influenza A, bocavirus) and three were positive in stool specimens 170 (astrovirus, rotavirus or picornavirus). Four of the children who did not have MD had other The median time taken to complete the near-patient meningococcal LAMP tests (from 178 starting extraction to reading results) was 1 hour 26 minutes. Results of near-patient testing 179 using meningococcal LAMP are shown in Table 4 . 141/148 children had a combined nasal 180
and throat swab taken and tested using the near-patient LAMP protocol. The performance 181 of near-patient nasopharyngeal testing (Table 4A ) was as follows: sensitivity 84% (95% CI 182 65-94); specificity 100% (95% CI 98-100); PPV 100% (95% CI 81-100); NPV 97% (95% 183 CI 91-99); positive LR ∞; negative LR 0.16 (95% CI 0.07-0.39). 144/148 children had 184 sufficient blood taken for testing using the near-patient LAMP protocol. The performance 185 of near-patient blood testing (Table 4B ) was: sensitivity 84% (95% CI 72-99); specificity 186 100% (95% CI 93-100); PPV 100% (95% CI 75-100); NPV 97% (95% CI 90-99); positive 187 LR ∞; negative LR 0.16 (95% CI 0.01-0.42). All 148 children had at least one specimen 188 (nasopharyngeal swab and/or blood) analysed in the near patient setting. If patients who 189
were positive by either of the near-patient tests were considered to be positive, the combined 190 performance of near-patient LAMP testing of blood and/or nasopharyngeal specimens 191 (Table 4C ) was: sensitivity 89% (95% CI 72-96); specificity 100% (95% CI 97-100); PPV 192 100% (95% CI 83-100); NPV 98% (95% CI 93-99); positive LR ∞; negative LR 0.11 (95% 193 Three patients with laboratory confirmed MD were negative by both near-patient LAMP 196 tests. Two had classical signs and symptoms of MD, and the third was an atypical 197 presentation; a two year-old girl recalled to the hospital when a blood culture taken the 198 previous day grew N. meningitidis. At first presentation, her WCC and CRP were normal, 199
and she was discharged on oral amoxicillin after a period of observation. When recalled 20 200 hours later, her parents reported that she had remained well since discharge. Physical 201 examination revealed no meningism, normal perfusion and a few non-blanching spots on 202 her abdomen. Her WCC had risen to 28.2 x 10 9 /l and CRP to 211 mg/l. Her nasopharyngeal 203 and blood specimens were both PCR positive for meningococcal DNA. The results of 'non-specific' laboratory tests are shown in Table 5 . Near-patient LAMP 208 testing was substantially more accurate than any of the routinely used non-specific tests for 209 diagnosis of MD. 210 gave impressive results. Comparison to WCC and CRP indicates that LAMP tests are more 214 useful than conventional non-specific tests for both ruling in and ruling out meningococcal 215 disease. In addition to being accurate, this study demonstrates that molecular testing in the 216 emergency department is feasible. The LAMP assay performed similarly well in the near-217 patient setting and the laboratory setting, using different extraction protocols and different 218 operators, with results typically available in less than two hours. We describe the accuracy 219 of meningococcal LAMP in terms of likelihood ratios, which are not affected by disease 220 prevalence. 17 Likelihood ratios greater than 10 and less than one are considered strong 221 evidence for the value of a diagnostic test. 18 By this metric, the near-patient LAMP assay 222 used here is clearly useful for diagnosis of MD. 223
224
There is likely to be resistance to testing of nasopharyngeal specimens for meningococcus 225 because of the potential to detect asymptomatic carriage. No carriage was detected during 226 this study. Although a larger study may have identified some carriage and reduced the 227 specificity from 100%, the data supports our previous conclusion that molecular testing of 228 nasopharyngeal specimens in very young children is diagnostically useful, and generally not 229 confounded by carriage. 14 A relatively non-invasive nasopharyngeal meningococcal LAMP 230 test on children presenting with 'fever without source' where the prevalence of 231 meningococcal disease is very low should perform with reasonable accuracy. In this context 232 a positive result is strongly suggestive of disease and could prompt further investigation and 233 treatment. Patients with a negative result could be discharged safely after a period of 234 observation, subject to the universal advice to re-attend if deterioration occurs. Most children with fever still present to their general practitioner where the prevalence of meningococcal 236 disease is much lower still. 19, 20 A non-invasive test with a strong negative likelihood ratio 237 used in combination with careful clinical assessment is likely to be even more valuable in 238 this context. 239
240
Our data support the cost minimisation analysis conducted by NICE which suggests that 241 rapid (<24 hours) access to molecular (PCR) test results can reduce costs through earlier 242 discharge of the relatively well patients. NICE conclude that "the infrastructure does not 243 currently exist to support such a strategy and is unlikely to exist within the next few years". 13 244
Meningococcal LAMP could be used immediately in any small to medium sized hospital 245 with access to a basic laboratory to give results within a few hours. The meningococcal 246 LAMP assay described here, used in combination with careful clinical assessment, could 247 have led to earlier discharge of a significant number of 'not unwell' patients in this study 248 who did not have MD. 249
250
Many of the MD cases in this study also had viral co-infections. As reported previously 21 251 we note that in the absence of rapid molecular testing for bacterial pathogens, positive 252 molecular virology test results for viruses such as enterovirus or picornavirus should not 253 reassure clinicians that an unwell patient does not have MD. 254
255
One limitation of our study was that the proportion of positive cases (19%) was lower than 256 a previous study in our unit (33%) although this confirms there was no bias towards more 257 severe case. The blood culture positive rate of ~25% is similar to previous studies 22,23 and 258 the 'PCR only' case ascertainment (77%) is slightly higher than reports from the national 259 reference laboratory 23 indicating a representative case mix of patients. We experienced historically low levels of meningococcal disease during this study, with only 36 confirmed 261 cases in Northern Ireland in 2011 compared with 94 cases in 2004. This has resulted in wider 262 confidence intervals for our estimates of diagnostic accuracy. A small number of discordant 263 test results were seen, which illustrates the problems that are common with definitive 264 diagnosis of MD, even using the best available reference laboratory tests. This study was 265 not designed to investigate whether early availability of definitive test results could influence 266 patient management and improve clinical outcomes. A larger multi-centre trial of near-267 patient LAMP for children presenting with 'fever without source' could address this 268 important question. Since this work was completed, the meningococcal LAMP test has been 269 developed further, using freeze-dried reagents, real-time detection and improved 270 amplification chemistry to improve sensitivity and reduce the assay time to below 20 271
minutes. 272 273
This study is the first to evaluate a rapid near-patient molecular diagnostic test for MD, and 274 also the first demonstration of near-patient testing using LAMP in a UK hospital. The data 275 support our initial hypothesis that testing of nasal and throat swabs using meningococcal 276 LAMP in a near-patient setting is useful as a rapid diagnostic test for N. meningitidis. LAMP 277 testing of nasopharyngeal or blood specimens in a near-patient setting was both feasible and 278 accurate, and combining the results for both specimen types further increased the diagnostic 279 accuracy. These data suggest the ability to rapidly detect a pathogenic (capsular) strain of N. 280 meningitidis in the nasopharynx of a febrile child whose parents are sufficiently concerned 281 to seek medical advice can give clinically useful information. Current advice from Public 282
Health England (PHE) and NICE on testing of respiratory specimens is inconsistent. PHE 283 recommends culture of nasopharyngeal swabs from suspected cases. 24 In contrast, NICE 284 explicitly recommend that nasopharyngeal specimens are not tested, by any method. 13 The potential to diagnose and treat life-threatening invasive disease early outweighs the small 286 risk of detecting asymptomatic carriage in young children, and this should be considered in 287 reviewed NICE guidance. Searching with the terms ((point of care AND meningococc*) OR (point of care AND 296 meningitidis)) found 7 papers, two reporting methods suitable for near-patient testing 8, 25 . 297
One of these 25 describes a LAMP-based testing system that "has potential" for point of care 298 testing, but presents no clinical validation data in either laboratory or near-patient settings. 299
The other 8 is the assay used here, and is the first published and clinically validated LAMP 300 assay for rapid detection of meningococcal DNA. This study is the first to evaluate such an 301 assay for near-patient testing. 302
303
Interpretation 304
305
There is currently no effective diagnostic test for meningococcal disease 2 . Cases with clear 306 signs and symptoms are (or should be) diagnosed clinically, and laboratory testing serves 307 mainly to confirm the clinical diagnosis. The decision to obtain and test sterile site 308 specimens (blood or CSF) presumes that a clinical suspicion of serious invasive disease already exists. No clinician who suspects meningococcal disease will wait for laboratory 310 results before starting antibiotic treatment, so testing simply confirms an existing diagnosis. 311 312 Unfortunately, in the absence of definitive diagnostic testing, children with non-specific 313 symptoms who are actually in the early stages of meningococcal disease are frequently 314 overlooked. Half of children with confirmed meningococcal infection have been seen by a 315 healthcare professional and either falsely reassured or discharged in the hours leading up to 316 their clinical diagnosis and treatment. 3 It seems self-evident that identifying and treating 317 these children earlier could improve clinical outcomes, although there is no data to confirm 318 this. Without an accurate diagnostic test for meningococcal disease, ideally delivered at 319 point-of-care, there is little prospect of identifying these cases earlier in a clinical trial. 320
321
This study confirms that molecular testing using LAMP to detect meningococcus is highly 322 sensitive and specific, and demonstrates this for the first time in the context of near-patient 323 here were selected to optimise sensitivity (10 mg/l) or specificity (60 mg/l) based on ROC analysis (data not shown). The reference normal range for WCC in our laboratory is 5 to 13 x 10 9 /l. Figure S1 . Negative (A) and positive (B) meningococcal LAMP reaction tubes.
Reference laboratory testing
Blood and CSF specimens were cultured according to UK standard methods 2,3 using an automated BacT/ALERT ® 3D Microbial Detection System with BacT/ALERT ® FA culture medium (bioMérieux, Marcy l'Etoile, France). Isolates were identified using the VITEK ® 
